EMBRACE is a randomized, controlled, multicenter clinical study evaluating the effect of renal denervation on clinical adverse events in hypertensive patients undergoing staged percutaneous coronary intervention (PCI) for multivessel coronary artery disease.
Age range
21 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Primary endpoint: Win Ratio of Hierarchical Composite Endpoint After Staged PCI
Timeframe: 2 Years post procedure
Primary safety endpoint : Major vascular access site complications
Timeframe: 30 days after staged PCI
Primary safety endpoint: Contrast-associated acute kidney injury (CA-AKI) (≥25% increase in serum creatinine within 48-72 hours)
Timeframe: 30 days after staged PCI
Primary safety endpoint: Renal artery complications
Timeframe: 30 days after staged PCI